Nitroglycerin In Dextrose Injection
NDC Package 51662-1332-1
Package Information
Nitroglycerin In Dextrose (nitroglycerin, dextrose) injection is nitroglycerin in 5% Dextrose Injection is indicated for treatment of peri-operative hypertension; for control of heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and ß-blockers; and for induction of intraoperative hypotension. This formulation utilizes a injection delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1332 and is authorized under FDA application NDA019970.
Identification & Billing
- RxCUI: 312004 - nitroglycerin 50 MG in 250 ML Injection
- RxCUI: 312004 - 250 ML nitroglycerin 0.2 MG/ML Injection
- RxCUI: 312004 - 250 ML NTG 0.2 MG/ML Injection
- RxCUI: 312004 - 250 ML TNG 0.2 MG/ML Injection
- RxCUI: 312004 - nitroglycerin 200 MCG/ML per 250 ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51662 - Hf Acquisition Co Llc, Dba Healthfirst
- 51662-1332 - Nitroglycerin In Dextrose
- 51662-1332-1 - 250 mL in 1 BOTTLE, GLASS
- 51662-1332 - Nitroglycerin In Dextrose
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51662-1332-1 identifies a specific commercial package of 250 ml in 1 bottle, glass of Nitroglycerin In Dextrose, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This injection is formulated for intravenous use and contains nitroglycerin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on November 26, 2018. The current certification is valid through December 31, 2026.
How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662133201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.